# Latigo Biotherapeutics Inc. (LTGO) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $14.57, market value $966 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Latigo Biotherapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -10.1%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 47.1%**. 47.1% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Growth
- **EPS growth (1 yr): -78.4%**. Earnings per share fell 78.4%.

## Financial health
- **Current ratio: 4.00** (quick 4.00). Current assets cover the next year's liabilities 4.00 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Latigo Biotherapeutics Inc. does not currently pay a dividend, but it returned -15.5% of its market value through buybacks over the last year.

## Price and momentum
- **From 52-week high: -43.8%** (9.9% above the low). Trading 44% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 36**. An RSI of 36 is neutral.

Live score and charts: https://foliofundamentals.com/analyzer?s=LTGO · Page: https://foliofundamentals.com/stocks/ltgo

Not investment advice.